Virchow Biotech Private Limited

Milestones

Home / Milestones

Journey of Virchow Biotech

1999

R&D Work on Biogenerics

Innovation Begins

Research and development work started at Vanderbilt, Nashville, Tennessee.

2001

Company Incorporation

Foundation Laid

Virchow Biotech was incorporated in India. R&D assets were transferred to India.

2003

Manufacturing Facility

Growth Initiated

Construction of the manufacturing facility at Gagillapur began.

2005

First Biogeneric Approval

Breakthrough Achieved

Virchow’s first Biogeneric approval for PDGF-BB.

2007

Product Expansion

Portfolio Grows

Additional Biogeneric Approvals for Teriparatide, PEG-Interferon. Customer base expansion.

2009

Portfolio Expansion

Global Reach

Expanded export base, diversified product range, and commercialization of Rasburicase.

2014

Regulatory Approvals

Standards Met

PICS Approval (Ukraine), INVIMA Approval, USFDA Approval obtained.

2017

Acquisition & Development

Strategic Move

Acquired Silvasorb product portfolio from Halyard Inc. and started vaccine development.

2019

Facility Expansion

Capacity Boost

PIC/s Approval Malaysia. Unit 3, 4, and 5 became operational.

R&D Work on Biogenerics

Innovation Begins
Research and development work started at Vanderbilt, Nashville, Tennessee.

Company Incorporation

Foundation Laid
Virchow Biotech was incorporated in India. R&D assets were transferred to India.

Manufacturing Facility

Growth Initiated
Construction of the manufacturing facility at Gagillapur began.

First Biogeneric Approval

Breakthrough Achieved
Virchow’s first Biogeneric approval for PDGF-BB.

Product Expansion

Portfolio Grows
Additional Biogeneric Approvals for Teriparatide, PEG-Interferon. Customer base expansion.

Portfolio Expansion

Global Reach
Expanded export base, diversified product range, and commercialization of Rasburicase.

Regulatory Approvals

Standards Met
PICS Approval (Ukraine), INVIMA Approval, USFDA Approval obtained.

Acquisition & Development

Strategic Move
Acquired Silvasorb product portfolio from Halyard Inc. and started vaccine development.

Facility Expansion

Capacity Boost
PIC/s Approval Malaysia. Unit 3, 4, and 5 became operational.